CORC  > 中国医学科学院 北京协和医学院
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Robson, M. E.; Tung, N.; Conte, P.; Im, S-A; Senkus, E.; Xu, B.; Masuda, N.; Delaloge, S.; Li, W.; Armstrong, A.
2019
卷号30期号:4页码:558-566
关键词breast cancer germline BRCA mutation overall survival PARP inhibitor olaparib tolerability
ISSN号0923-7534
DOI10.1093/annonc/mdz012
URL标识查看原文
收录类别SCIE ; PUBMED
内容类型期刊论文
URI标识http://www.corc.org.cn/handle/1471x/6344636
专题中国医学科学院 北京协和医学院
推荐引用方式
GB/T 7714
Robson, M. E.,Tung, N.,Conte, P.,et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J],2019,30(4):558-566.
APA Robson, M. E..,Tung, N..,Conte, P..,Im, S-A.,Senkus, E..,...&Domchek, S. M..(2019).OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.,30(4),558-566.
MLA Robson, M. E.,et al."OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer".30.4(2019):558-566.
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace